Methods and Designs of Modern Breast Cancer Confirmatory Trials
暂无分享,去创建一个
M. Cortet | G. Freyer | J. Péron | B. You | T. Reverdy | Colette Smenteck | Marion Cortet
[1] E. Winer,et al. Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Kesselheim,et al. Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs , 2020, EClinicalMedicine.
[3] P. Fasching,et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. , 2019, The New England journal of medicine.
[4] M. Taphoorn,et al. Current state of quality of life and patient-reported outcomes research. , 2019, European journal of cancer.
[5] P. Neven,et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 , 2019, JAMA oncology.
[6] Vinay Prasad,et al. An Overview of Cancer Drugs Approved by the US Food and Drug Administration Based on the Surrogate End Point of Response Rate. , 2019, JAMA internal medicine.
[7] A. Kesselheim,et al. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. , 2019, JAMA internal medicine.
[8] J. Doctor,et al. The Value of Progression-Free Survival in Metastatic Breast Cancer: Results From a Survey of Patients and Providers , 2019, MDM policy & practice.
[9] E. Perez,et al. Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis. , 2019, The Lancet. Oncology.
[10] M. Stockler,et al. Effect Sizes Hypothesized and Observed in Contemporary Phase III Trials of Targeted and Immunological Therapies for Advanced Cancer , 2018, JNCI cancer spectrum.
[11] H. Naci,et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13 , 2017, British Medical Journal.
[12] C. Booth,et al. Approvals in 2016: questioning the clinical benefit of anticancer therapies , 2017, Nature Reviews Clinical Oncology.
[13] Elias Mossialos,et al. Assessment of Overall Survival, Quality of Life, and Safety Benefits Associated With New Cancer Medicines , 2017, JAMA oncology.
[14] F. Fiteni,et al. Surrogate end points for overall survival in breast cancer trials: A review. , 2016, Breast.
[15] S Michiels,et al. Progression-free survival as surrogate end point for overall survival in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] Virginia G Kaklamani,et al. Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. , 2015, The New England journal of medicine.
[17] C. Davis. Drugs, cancer and end-of-life care: A case study of pharmaceuticalization? , 2015, Social science & medicine.
[18] M. Ellis,et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. , 2015, The New England journal of medicine.
[19] J. Cylus,et al. Raising the bar for market authorisation of new drugs , 2012, BMJ : British Medical Journal.
[20] G. Pond,et al. Quality of reporting of modern randomized controlled trials in medical oncology: a systematic review. , 2012, Journal of the National Cancer Institute.
[21] A. Kesselheim,et al. Reputation and precedent in the bevacizumab decision. , 2011, The New England journal of medicine.
[22] M. Buyse,et al. Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] M. Buyse,et al. Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.